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and cardiovascular disease amongst others. Treatment effects and
cohort characteristics (mean age 63.1 years, diabetes duration
12.8 years, HbA1c 8.17%, BMI 30.3 kg/m2) were based on the
German cohort of the PREDICTIVE (Predictable Results and
Experience in Diabetes through Intensiﬁcation and Control to
Target: an International Variability Evaluation) study. Direct
medical costs were derived from published sources and expressed
in 2006 Euro (€) values. Projections were made over a 35-year
time horizon. Future costs and clinical beneﬁts were discounted
at 3.5% annually. Sensitivity analyses were performed.
RESULTS: Treatment with IAsp was projected to improve
quality-adjusted life expectancy by approximately 0.10 quality-
adjusted life years (QALYs) (6.06  0.09 versus 5.96  0.09
QALYs). Increased treatment costs with IAsp were partially
offset by cost savings due to reductions in the cumulative inci-
dence of diabetes-related complications. Over patient lifetimes,
mean direct medical costs were projected to increase by
approximately €1,274 per patient with IAsp versus HSI
(€45,423  1,354 versus €44,149  1,391). This resulted in
an incremental cost-utility ratio of €13,305 per QALY gained.
CONCLUSION: Over patient lifetimes, IAsp treatment was
projected to result in fewer diabetes-related complications
and improved quality-adjusted life expectancy compared to
HSI. Based on currently accepted willingness-to-pay limits, IAsp
would represent good value for money in the German setting.
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OBJECTIVES: An objective of the INSTIGATE study is to
describe the resource utilisation associated with care for type 2
diabetes in the 6 months before and after insulin initiation. This
abstract presents data from patients enrolled in Germany
and UK. METHODS: INSTIGATE is an ongoing prospective
European observational study investigating patients with type 2
diabetes who have initiated insulin during usual care. Data on
resource use for diabetes was collected at baseline retrospectively
for the 6 months prior to initiating insulin and at 3 and 6 months
following insulin initiation. RESULTS: In all, 509 patients were
enrolled in Germany and UK. 6 month follow-up data was
collected from 457 patients. The following changes in health care
professional consultations were observed in the 6 months before
and after insulin initiation: The % of patients with a visit to a
primary care doctor declined from 93.4% to 83.7% in Germany,
and in the UK from 79.4% to 48.2%. Visits to specialist nurses
increased in Germany from 52.3% to 91.4%, and in the UK from
77.5% to 81.7 % of patients. In both countries the % of patients
having phone calls with a specialist nurse increased; from 11.7%
to 50.6% in Germany and from 21.3% to 75.9% in UK. The %
of patients using a blood glucose monitor and the median weekly
number of test strips used increased in both countries, most
notably in Germany from 76.6% of patients testing 4 times a
week before insulin initiation to 99.6% of patients testing 21
times per week 6 months after insulin initiation. CONCLU-
SION: The type of health care professionals visited and nature of
the consultations changed in both countries following insulin
initiation; the % of patients having visits to primary care pro-
viders decreased and the % of patients having visits and phone
calls to specialist nurses increased.
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OBJECTIVES: This study, conducted in Type 2 diabetes mellitus
(T2DM), evaluated the cost utility of glargine versus NPH in
previously insulin naïve (IN) and non insulin naïve (NIN)
patients switching from NPH to insulin glargine in the UK using
observational data. The study assessed the combined effect of
HbA1c and hypoglycaemia reduction. METHODS: A discrete
event life time simulation based on UKPDS 68 was adapted to
include the effects of HbA1c and hypoglycaemia reduction using
published meta-regression results from 11 randomised clinical
trials. Direct costs and health utility (EQ5D) were derived from
published sources and the HODaR database respectively; costs
and beneﬁts were discounted at 3.5%. This model used the
demographic and efﬁcacy proﬁles of T2DM patients who were
IN or NIN who switched from NPH to glargine identiﬁed via the
THIN database. Analysis was conducted on 1,496 and 174 IN
and NIN patients respectively; the primary outcome measure was
Hba1c change. As hypoglycaemia was not directly collected from
the THIN database, sensitivity analysis was performed taking
into account HbA1c beneﬁt only. RESULTS: The mean age and
duration of diabetes at switch was 63 years and 7.5 years (IN)
and 70 years and 10.2 years (NIN) respectively. After adjustment
for baseline proﬁles IN patients starting glargine showed a sig-
niﬁcant reduction in HbA1c of 0.21% (p = 0.029) 12 months
post initiation versus NPH. For NIN patients switching from
NPH to glargine the adjusted HbA1c reduction was 0.46%
(p = 0.0093). The cost per QALY for a simulated cohort of
10,000 patients was £5,806 and £3,415 for IN and NIN patients.
In sensitivity analysis considering an HbA1c reduction only the
cost per QALY was £18,179 and £7,973 for IN and NIN patients
respectively. CONCLUSION: Based on real life observational
data, in both IN and NIN patients T2DM patients, glargine is
cost-effective compared to NPH.
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OBJECTIVES: This study tested a method to measure the vari-
ability of data among countries, and to assess the generalisability
of cost evaluation results. METHODS: The ﬁrst step of the
method consisted in identifying, within cost evaluations, all the
factors potentially responsible for variability among locations.
The second step consisted in selecting, among all potential trans-
ferability factors, the ﬁnal transferability factors which generated
variability, impacted on outcomes of economic evaluation, and
were both measurable and distinguishable from other factors.
The third step was the identiﬁcation of transferability areas
as sets of homogeneous ﬁnal transferability factors. Both the
Euclidean metric and Principal Components Analysis were used
in the fourth step to explore the generalisability of the results.
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The method was applied to a high-cost innovation in oncology
currently under development in ﬁve European countries, carbon
ion radiotherapy. RESULTS: 138 potential factors identiﬁed, 116
ﬁnal factors were analysed and regrouped into 9 areas. The
Principal Components Analysis between countries 1 and 2, and
between 4 and 5, showed proximity between the costs of equip-
ment and the cost of buildings. A large variation was observed
using the Euclidean metric between countries 1 and 2, especially
for working time, and between countries 4 et 5 for the use
of personnel resources. On the opposite, a low distance was
observed between countries 2 and 4 for treatment capacity, and
between countries 2 and 3 for technology availability and costs
of personnel. CONCLUSION: Using this method we could assess
the generalisability of the cost of carbon ion radiotherapy, and
we identiﬁed factors and areas that limited this generalisability.
This study also showed the necessity to integrate recommenda-
tions in order to increase the generalisability of economic evalu-
ations in health care.
MC2
BAYESIAN MODELING OF RESOURCE USE ALONGSIDE
MULTINATIONAL RANDOMISED CLINICALTRIALS
Gauthier A1, Manca A2,Anton SF3, Dewberry H4
1i3 Innovus, Uxbridge, Middlesex, UK, 2University of York,York, UK,
3Boehringer-Ingelheim, Ridgeﬁeld, CT, USA, 4Boehringer Ingelheim
Limited, Bracknell, Berkshire, UK
OBJECTIVES: Most cost-effectiveness analyses conducted
alongside multinational randomized controlled clinical trials
(RCTs) are carried out applying the unit costs from the country
of interest to each resource item with the objective of estimating
total health care by treatment group. An alternative is to model
health care resource use (HCRU) directly rather than expressed
in monetary units. This study aimed to model HCRU collected
alongside RCTs, accounting for their speciﬁc distributions and
the hierarchical structure of the data. METHODS: The analysis
was conducted using data from multinational RCTs enrolling
approximately 2000 patients suffering from a chronic disease.
For each HCRU, appropriate distribution functions were identi-
ﬁed based on the deviance of the univariate model (including
treatment effect only). Standard models were extended to the
Bayesian multi-level models (MLM) settings, whereby covariates
at different levels (patient, centre and country) were introduced
as predictors. RESULTS: Depending on the treatment group,
69% to 71% of patients had no GP visits. The Poisson distribu-
tion under-estimated the proportion of zeros by 18%, whereas
the negative binomial (NB) and zero-inﬂated Poisson (ZIP)
provided good matches. The greater ﬂexibility of ZIP models
provided signiﬁcantly better ﬁt than NB. ZIP was the best distri-
bution to model health care resource contacts and the zero
inﬂated Poisson overdispersed (ZIPO) function was best repre-
senting concomitant medications treatment days. GP visits pre-
sented the highest heterogeneity between countries (9% of the
variance was explained by the country effect) and this was well
captured by the MLMs. CONCLUSION: Misspeciﬁcation of
statistical models may result in biased parameters and misleading
inference. This study proposed the development of ZIP and ZIPO
MLMs to model HCRU alongside RCTs. To obtain more precise
estimates, multivariate analyses of HCRU could be conducted
and other sources of evidence could be used additionally, external
to the clinical studies.
MC3
THE DEVELOPMENT OF AN INCREMENTAL WILLINGNESS
TO PAY CURVE DERIVED FROM A DISCRETE
CHOICE EXPERIMENT
Regier DA1, Marra CA2, Ryan M1
1University of Aberdeen, Aberdeen, Scotland, UK, 2University of British
Columbia,Vancouver, BC, Canada
OBJECTIVES: The purpose of this study was to investigate the
development of an incremental willingness to pay curve (IWTPC)
using parameters obtained from a discrete choice experiment
(DCE). METHODS: The DCE was structured around a novel
genetic technology that identiﬁes genetic causes of developmental
delay (DD). The DCE included three alternatives. The ﬁrst two
alternatives differed on three attributes: number of children
receiving a genetic diagnosis, time waiting for results, and cost.
The third alternative was an opt-out option to allow for non-
demanders. A mixed logit (MXL) behavioural model was speci-
ﬁed to incorporate preference heterogeneity, and hierarchical
Bayes (HB) was employed to estimate the joint posterior of
parameter partworths. The opt-out parameter was assumed to
follow a normal distribution, a truncated normal was given to
number of children diagnosed and waiting time, and the log
normal distribution was assumed for cost. The HB procedures
employed allow for the direct estimation of each individual’s
parameter estimates, which are transformed into an incremental
willingness to pay (WTP) value. Under certain assumptions, the
IWTPC represents the incremental WTP that each individual in
society has for the technology under a given scenario. RESULTS:
A total of 796 respondents from the general public were recruited
using a research ﬁrm in British Columbia, Canada. Each respon-
dent completed 16 choice questions. The parameter estimates
revealed a considerable amount of preference heterogeneity,
which indicated that the mean incremental WTP estimate might
not accurately represent society’s WTP. Individual WTP ranged
from $28 to $12,000 for an increase in 14 children identiﬁed to
have a genetic cause of DD and a 1-week reduction in waiting
time. Fifty-one percent of respondents had an incremental WTP
of at least $1041 for the scenario. CONCLUSION: Using the
joint posterior of preference partworths, the IWTPC is a prom-
ising tool to characterize the value of a health care good.
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OBJECTIVES: The increasing use of full economic evaluations
has lead to the development of various instruments to assess their
quality. In addition to the much used British Medical Journal
(BMJ) check-list, two new instruments were recently developed:
the Consensus Health Economic Criteria (CHEC) list and the
Quality of Health Economic Studies (QHES) instrument. The
purpose of this study was to compare these three instruments as
quantitative tools to measure the quality of economic evalua-
tions. The analysis was performed through a systematic review of
economic evaluations of the surgical treatment of obesity.
METHODS: Quality of 9 selected studies was assessed indepen-
dently by two health economist experts. Rater 1 repeated the
analysis after 8 weeks. The spearman rank correlation coefﬁcient
was used at time 1 and 2 to compare the instruments, and for
each instrument, the intraclass correlation coefﬁcient (ICC(3,1))
to assess test-retest reliability between time 1 and 2. For each
instrument, the interrater agreement was estimated at two levels:
comparison of the total score of each article by the ICC(2,1) and
comparison of results per item by kappa values. RESULTS:
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